Literature DB >> 30697132

Association of Procalcitonin Value and Bacterial Coinfections in Pediatric Patients With Viral Lower Respiratory Tract Infections Admitted to the Pediatric Intensive Care Unit.

John J Kotula, Wayne S Moore, Arun Chopra, Jeffrey J Cies.   

Abstract

OBJECTIVE: Our primary objective was to determine the utility of procalcitonin (PCT) in detection of bacterial coinfection in children < 5 years admitted to the pediatric intensive care unit with viral lower respiratory tract infection (LRTI).
METHODS: Electronic medical record review of children < 5 years admitted to the pediatric intensive care unit with a viral LRTI who also had at least 1 PCT concentration measurement.
RESULTS: Seventy-five patients were admitted to the intensive care unit and met the inclusion criteria for this investigation. The PCT threshold concentrations of 0.9, 1, 1.4, and 2 ng/mL were found to be statistically significant in determining the presence of a bacterial coinfection. The PCT concentration with the most utility was 1.4 ng/mL with sensitivity, specificity, positive and negative predictive values of 46%, 83%, 68%, and 76%, respectively. For patients with serial PCTs, the second PCT correctly influenced treatment decisions for 11 of 25 patients (44%).
CONCLUSIONS: A PCT value of 1.4 ng/mL determined the presence of a bacterial coinfection primarily owing to the high specificity and negative predictive value. Our data add evidence to the relatively high negative predictive value of PCT concentrations in identifying patients with bacterial coinfection, specifically in the case of viral LRTI. In addition, our preliminary data indicate serial PCT measurements may help further influence correct treatment decisions. Prospective, controlled studies are warranted to validate an appropriate PCT threshold concentration to help in identifying bacterial coinfection as well as to further explore the role of serial PCT values in determining the absence or presence of a bacterial coinfection.

Entities:  

Keywords:  lower respiratory tract infection; pediatric; procalcitonin

Year:  2018        PMID: 30697132      PMCID: PMC6336174          DOI: 10.5863/1551-6776-23.6.466

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  15 in total

1.  Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome.

Authors:  R Arkader; E J Troster; M R Lopes; R R Júnior; J A Carcillo; C Leone; T S Okay
Journal:  Arch Dis Child       Date:  2005-12-02       Impact factor: 3.791

2.  Procalcitonin use in a pediatric intensive care unit.

Authors:  Jeffrey J Cies; Arun Chopra
Journal:  Pediatr Infect Dis J       Date:  2014-09       Impact factor: 2.129

3.  Hospitalizations for severe lower respiratory tract infections.

Authors:  Adena H Greenbaum; Jufu Chen; Carrie Reed; Suzanne Beavers; David Callahan; Deborah Christensen; Lyn Finelli; Alicia M Fry
Journal:  Pediatrics       Date:  2014-08-11       Impact factor: 7.124

4.  Incidence of bacterial coinfection with respiratory syncytial virus bronchopulmonary infection in pediatric inpatients.

Authors:  Haruka Hishiki; Naruhiko Ishiwada; Chie Fukasawa; Katsuaki Abe; Tadashi Hoshino; Jiro Aizawa; Nobuyasu Ishikawa; Yoichi Kohno
Journal:  J Infect Chemother       Date:  2010-08-11       Impact factor: 2.211

5.  Comparison between procalcitonin and C-reactive protein for early diagnosis of children with sepsis or septic shock.

Authors:  José R Fioretto; Joelma G Martin; Cilmery S Kurokawa; Mário F Carpi; Rossano C Bonatto; Marcos A de Moraes; Sandra M Q Ricchetti
Journal:  Inflamm Res       Date:  2010-02-04       Impact factor: 4.575

6.  Procalcitonin in young febrile infants for the detection of serious bacterial infections.

Authors:  Vincenzo Maniaci; Andrew Dauber; Scott Weiss; Eric Nylen; Kenneth L Becker; Richard Bachur
Journal:  Pediatrics       Date:  2008-10       Impact factor: 7.124

7.  Procalcitonin to predict bacterial coinfection in infants with acute bronchiolitis: a preliminary analysis.

Authors:  James L Laham; Patrick J Breheny; Brian M Gardner; Henrietta Bada
Journal:  Pediatr Emerg Care       Date:  2014-01       Impact factor: 1.454

Review 8.  Procalcitonin as a marker of severe bacterial infection in children in the emergency department.

Authors:  Jamie N Deis; Clarence B Creech; Cristina M Estrada; Thomas J Abramo
Journal:  Pediatr Emerg Care       Date:  2010-01       Impact factor: 1.454

9.  Trends in bronchiolitis hospitalizations in the United States, 2000-2009.

Authors:  Kohei Hasegawa; Yusuke Tsugawa; David F M Brown; Jonathan M Mansbach; Carlos A Camargo
Journal:  Pediatrics       Date:  2013-06-03       Impact factor: 7.124

10.  Procalcitonin guidance to reduce antibiotic treatment of lower respiratory tract infection in children and adolescents (ProPAED): a randomized controlled trial.

Authors:  Gurli Baer; Philipp Baumann; Michael Buettcher; Ulrich Heininger; Gerald Berthet; Juliane Schäfer; Heiner C Bucher; Daniel Trachsel; Jacques Schneider; Muriel Gambon; Diana Reppucci; Jessica M Bonhoeffer; Jody Stähelin-Massik; Philipp Schuetz; Beat Mueller; Gabor Szinnai; Urs B Schaad; Jan Bonhoeffer
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

View more
  5 in total

1.  Low Levels of Procalcitonin Are Related to Decreased Antibiotic Use in Children Hospitalized Due to Influenza.

Authors:  August Wrotek; Oliwia Wrotek; Teresa Jackowska
Journal:  Diagnostics (Basel)       Date:  2022-05-05

2.  Serum Procalcitonin as a Predictive Biomarker in COVID-19: A Retrospective Cohort Analysis.

Authors:  Aaiz Hussain; Lavi Singh; James McAlister Iii; Yongho Jo; Tadevos T Makaryan; Shaheer Hussain; Robert W Trenschel; Marc M Kesselman
Journal:  Cureus       Date:  2022-08-09

3.  Incidence and association of ocular manifestations with the disease severity in COVID-19 patients of northern region of India.

Authors:  Aalok Kumar; Lavanya Anuranjani
Journal:  Taiwan J Ophthalmol       Date:  2022-05-19

4.  Ocular manifestations of coronavirus disease 2019.

Authors:  Basak Bostanci Ceran; Serdar Ozates
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-06-06       Impact factor: 3.535

5.  Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.

Authors:  Giuseppe Lippi; Mario Plebani
Journal:  Clin Chim Acta       Date:  2020-03-04       Impact factor: 3.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.